Concepedia

Nadia Sattar

NS

5

Publications

935

Citations

5

H-Index

2010

Active since

Affiliations

Alexion Pharmaceuticals (United States)(Current)

National Hospital Organization Hanamaki Hospital

International University of Health and Welfare

University of Münster

Fondazione IRCCS Istituto Neurologico Carlo Besta

Nadia Sattar is an author at Alexion Pharmaceuticals (United States) specializing in medicine, autoimmunity, and autoimmune disease.

Top concepts

Publications per year

2010–2020

5

Publications

5

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

, , +3

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

Celiac Disease in Children, Adolescents, and Young Adults with Autoimmune Thyroid Disease

Nadia Sattar, Farrah Lazare, Martina Kacer et al. · The Journal of Pediatrics · 2010 · 67 citations

, , +7

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki et al. · Journal of the Neurological Sciences · 2019 · 23 citations · Full text

Rows per page

1–5 of 5